article Open AccessTop 1% cited
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
The Lancet Oncology · 2017 · Vol. 18(11) · pp. 1493–1501
Hussein A. Tawbi✉(The University of Texas MD Anderson Cancer Center)Melissa Burgess(University of Pittsburgh)Vanessa Bolejack(Cancer Research And Biostatistics)Brian A. Van Tine(Washington University in St. Louis)Scott M. Schuetze(University of Michigan–Ann Arbor)James Hu(University of Southern California)Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center)Steven Attia(WinnMed)Richard F. Riedel(Duke University)Dennis A. Priebat(MedStar Washington Hospital Center)Sujana Movva(Fox Chase Cancer Center)Lara E. Davis(Oregon Health & Science University)Scott H. Okuno(Mayo Clinic in Florida)Damon R. Reed(Moffitt Cancer Center)John Crowley(Cancer Research And Biostatistics)Lisa H. Butterfield(University of Pittsburgh)Ruth Salazar(The University of Texas MD Anderson Cancer Center)Jaime Rodriguez‐Canales(The University of Texas MD Anderson Cancer Center)Alexander J. Lazar(The University of Texas MD Anderson Cancer Center)Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center)Laurence H. Baker(University of Michigan–Ann Arbor)Robert G. Maki(Hofstra University)Denise K. Reinke(Sarcoma Alliance for Research through Collaboration)Shreyaskumar Patel(The University of Texas MD Anderson Cancer Center)
Sarcoma Diagnosis and TreatmentCAR-T cell therapy researchCancer Immunotherapy and BiomarkersMedicineSarcomaPembrolizumabSoft tissue sarcomaBone SarcomaSurgeryClinical endpointSoft tissueInternal medicineCohort
MeSH terms
Academic Medical CentersAdultAgedBone NeoplasmsDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansInfusions, IntravenousMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPrognosisSarcoma
Citations
1,375
FWCI
76.47
field-weighted impact
References
42
Percentile
100%
vs. same field & year
Citations per year
References
Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
Annals of Surgery · 1989 · 1,007 citations
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
The Lancet · 2015 · 6,477 citations
Nonparametric Estimation from Incomplete Observations
Journal of the American Statistical Association · 1958 · 38,793 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.